Hemostatic Action of OC-108, a Novel Agent for Hemorrhoids, Is Associated With Regional Blood Flow Arrest Induced by Acute Inflammation

DOI Web Site 被引用文献4件 参考文献16件
  • Ono Takashi
    Pharmaceuticals Research Division, Mitsubishi Pharma Corporation, Japan
  • Nakagawa Haruto
    Pharmaceuticals Research Division, Mitsubishi Pharma Corporation, Japan
  • Fukunari Atsushi
    Pharmaceuticals Research Division, Mitsubishi Pharma Corporation, Japan
  • Hashimoto Toshio
    Pharmaceuticals Research Division, Mitsubishi Pharma Corporation, Japan
  • Komatsu Hirotsugu
    Pharmaceuticals Research Division, Mitsubishi Pharma Corporation, Japan

この論文をさがす

抄録

Clinically, hemorrhoidal bleeding and prolapse disappeared immediately after injection of the sclerosing agent OC-108 into submucosa of hemorrhoids. The aim of this study was to elucidate the mechanism of action responsible for the immediate hemostatic effect of OC-108 using anesthetized rats. Subcutaneous injection of OC-108 in rats decreased blood flow at the injection site within 5 min. Aluminum potassium sulfate, one of the main ingredients of OC-108, reduced the skin blood flow. However, tannic acid, another main ingredient, did not. By perfusion of OC-108 on the mesenteric surface, microcirculatory blood flow was arrested without remarkable change in blood vessel diameter, accompanied by increased vascular permeability and venous hematocrit. These results indicate that OC-108 induces regional blood flow arrest with rapid onset, this effect being attributed to the action of aluminum potassium sulfate, and that hemoconcentration due to increased vascular permeability (plasma extravasation), an acute inflammatory reaction, is involved in the mechanisms of the immediate hemostatic action of OC-108.<br>

収録刊行物

被引用文献 (4)*注記

もっと見る

参考文献 (16)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ